FDA Drug recall D-0833-2020
Lamotrigine Tablets, USP, 100 mg, Rx Only, 100-count bottle, Mfd. by: Taro Pharmaceutical Industries Ltd
- FDA Drug
- Class I
- terminated
- Published 2020-02-19
On 2020-02-19 the FDA classified a Class I recall of Lamotrigine Tablets, USP, 100 mg, Rx Only, 100-count bottle, Mfd. by: Taro Pharmaceutical Industries Ltd by Taro Pharmaceuticals U, citing cross Contamination; Lamotrigine Tablets 100 mg USP was contaminated with enalapril maleate.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0833-2020 |
| Classification | Class I |
| Status | terminated |
| Initiated | 2019-12-20 |
| Published | 2020-02-19 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Taro Pharmaceuticals U |
| Distribution | US |
Product
Lamotrigine Tablets, USP, 100 mg, Rx Only, 100-count bottle, Mfd. by: Taro Pharmaceutical Industries Ltd. Haifa Bay, Israel 2624761 Dist. by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532, NDC 51672-4131-1.
Reason
Cross Contamination; Lamotrigine Tablets 100 mg USP was contaminated with enalapril maleate.
Identifiers
| ndc | 51672-4130-6 |
|---|---|
| ndc | 51672-4130-4 |
| ndc | 51672-4130-1 |
| ndc | 51672-4130-3 |
| ndc | 51672-4130-0 |
| ndc | 51672-4131-6 |
| ndc | 51672-4131-4 |
| ndc | 51672-4131-1 |
| ndc | 51672-4131-3 |
| ndc | 51672-4131-0 |
| ndc | 51672-4132-6 |
| ndc | 51672-4132-4 |
| ndc | 51672-4132-1 |
| ndc | 51672-4132-2 |
| ndc | 51672-4132-3 |
| ndc | 51672-4132-0 |
| ndc | 51672-4133-6 |
| ndc | 51672-4133-4 |
| ndc | 51672-4133-1 |
| ndc | 51672-4133-2 |
| ndc | 51672-4133-3 |
| ndc | 51672-4133-0 |
| code_info | Lot #: 331771, Exp. June 2021 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0833-2020%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.